Drug Profile


Alternative Names: IST-1097; MDX-1097; MDX-1097 (kappa)

Latest Information Update: 23 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune System Therapeutics; Medarex
  • Developer HaemaLogiX
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 08 Sep 2016 HaemaLogiX plans a phase IIb trial for Multiple myeloma (Second-line therapy, Combination therapy) in Australia (ACTRN12616001164482p)
  • 14 Aug 2015 Phase-II development for Multiple myeloma is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top